2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Friday, March 20, 2026

4:55PM-5:00PM: Abstract Number: 098

Investigating S100 Proteins as Biomarkers for Pediatric Localized Scleroderma

Abstracts: Pediatric Rheumatology Potpourri

4:55PM-5:00PM: Abstract Number: 116

Pilot of Adalimumab Withdrawal (PAW): Preliminary Analysis of Feasibility and Acceptability of Self-Collected Capillary Blood Samples

Abstracts: Technology

5:00PM-6:00PM: Abstract Number: 087

A Growing Problem: Factors Associated with Growth Disturbances in Juvenile Localized Scleroderma

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 096

Acute Care Utilization in New-Onset Childhood Systemic Lupus Erythematosus: Insights from a Pilot Study

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 103

Anifrolumab Use in Youngsters with Rheumatic Conditions: Case Series and a Review of the Evidence Base

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 086

APOL1 Focal Segmental Glomerulosclerosis Requiring Renal Transplant, the Burden of Childhood onset Autoimmune and Autoinflammatory Disease

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 122

Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children

Posters: Quality, Health Services, and Education Research II

5:00PM-6:00PM: Abstract Number: 112

Burden of Latent and Active TB in Pediatric TNF-Inhibitor Therapy: A Decade of Real-World Data from a Tertiary Care Centre

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 090

Characterizing CNS MRI Abnormalities in Pediatric ANCA-Associated Vasculitis

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 106

Clinical Characteristics and Safety Outcomes in Refractory Kawasaki Disease Treated with Second-Dose Infliximab

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 099

Clinical Features of Juvenile Antisynthetase Syndrome: A Single-Center Case Series

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 088

Demographics and Clinical Features of Deficiency of adenosine deaminase 2: A Large Quaternary Single Center Experience

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 084

Early Life Exposures and Risk of Spondyloarthritis: A Population-Based Case-Control Study

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 097

Evaluating Associations between Diffusion Tensor Imaging Metrics and Cognitive Function in Youth with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

Posters: Clinical and Therapeutic Aspects II

5:00PM-6:00PM: Abstract Number: 119

Expansion of Mental Health Screening to Patients with Diverse Rheumatologic Diagnoses in an Outpatient Pediatric Rheumatology Clinic

Posters: Quality, Health Services, and Education Research II

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].